Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03639766 · ClinicalTrials.gov registry record · Phase 4
The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon
A Phase 4 study, sponsored by University of Central Florida.
- Terminated
- Registry status
- Phase 4
- Development phase
- 3
- Enrollment target
NCT03639766: Clinical Trial Phase 4 study, sponsored by University of Central Florida.
NCT03639766 is a Phase 4 study that was terminated before completion, run by University of Central Florida. The registered enrollment target is 3 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03639766, a Phase 4 study, was terminated before completion, sponsored by University of Central Florida.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 3 participants
- Enrollment target
Study Summary
This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.
Primary Outcome
Raynaud's Condition Score is a validated outcome measure used to assess a person's functionality owing to their Raynaud's symptoms. 0 to 10, with 0 being no symptoms and 10 being more severe symptoms of Raynaud's.
Interventions
- DRUG AbobotulinumtoxinA
- OTHER Saline solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-08-31 |
| Est. Completion | 2020-01-31 |
| Phase | Phase 4 |
Why NCT03639766 stopped before completion
NCT03639766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which AbobotulinumtoxinA is the first listed.
NCT03639766 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03639766 about?
NCT03639766 is a clinical study titled "The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's Phenomenon". This study aims to investigate the effect of abobotulinum toxin A on the symptoms of Raynaud's phenomenon.
What is the current status of trial NCT03639766?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 3 participants. The study started on 2018-08-31. Estimated completion is 2020-01-31.
What interventions are being tested in trial NCT03639766?
The interventions under investigation include: AbobotulinumtoxinA (DRUG), Saline solution (OTHER).
Who is sponsoring clinical trial NCT03639766?
This trial is sponsored by University of Central Florida, which has 91 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03639766's enrollment target sits among peer trials
3 1995th of 2000 higher than 3 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI